Creating a living biobank of lung cancer organoids
Official title: Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)
Run by The University of Texas Health Science Center at San Antonio · NCT03655015 · Data updated 2026-11-12
This study is trying to create a collection of lung cancer samples from patients to help with future research and understand more about the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | The University of Texas Health Science Center at San Antonio Academic / other |
| Locations | 1 site (San Antonio, Texas) |
| Status | Recruiting |
| Started | October 16, 2018 |
| Main results expected | December 1, 2028 |
| Study ends | December 1, 2029 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT03655015 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients aged 18 and older with a diagnosis of lung cancer or related conditions who are undergoing standard treatment.
✕Probably not a fit
Patients who are not undergoing tumor resection or systemic treatment as part of their standard care may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a living biobank of patient-derived organoids (PDOs) from individuals diagnosed with Stage I-IV lung cancer. By enrolling at least 50 patients, the researchers will collect tumor specimens during surgery and culture these organoids for future experiments. The study will also analyze circulating tumor cells (CTCs) and gather patient demographic information, treatment history, and survival data through questionnaires. No specific treatment will be provided as part of this observational study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lung cancer treatment responses and improve personalized treatment strategies.
How similar studies have gone: Other studies utilizing patient-derived organoids have shown promise in understanding cancer biology and treatment responses, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure. * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care * Any clinical stage of lung cancer * Adult patients ≥18 years of age * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history Exclusion Criteria: * At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
Where it's running
-
UT Health San Antonio, M.D. Anderson Cancer Center
San Antonio, Texas, United States Recruiting
Study contacts
- Principal investigator: Josephine Taverna, MD — UT Health San Antonio M.D. Anderson Cancer Center
- Study coordinator: Josephine Taverna, MD
- Email: tavernaj@uthscsa.edu
- Phone: 210-450-8234
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A new treatment model for elderly lung cancer patients
This trial tests a comprehensive, integrated care approach for older adults with lung cancer to improve perioperative management and outcomes.
-
Investigational antibody–drug conjugates for previously treated stage IV squamous non-small cell lung cancer
This trial tests whether antibody–drug conjugates can shrink or control metastatic squamous non-small cell lung cancer in people whose cancer progressed after immunotherapy and platinum chemotherapy.
-
Ventilation imaging to guide lung radiotherapy in non-small cell lung cancer
This study tests whether using lung ventilation imaging can help plan radiotherapy for people with stage II–IV NSCLC to reduce lung toxicity.
-
Bright-light exposure and exercise program for cancer patients
This study is testing if a six-week program that combines bright-light exposure with exercise can help people with lung and esophageal cancer feel better and improve their quality of life.
-
Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations
This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.
-
Registry for thoracic surgery procedures in Spain
This study is creating a national database to see how new surgical techniques and technologies in thoracic surgery can improve care and outcomes for patients in Spain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.